August 1994
Volume 35, Issue 9
Free
Articles  |   August 1994
Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy.
Author Affiliations
  • G N Pomerance
    Plaza Eye Center, Chattanooga, Tennessee.
  • D W Evans
    Plaza Eye Center, Chattanooga, Tennessee.
Investigative Ophthalmology & Visual Science August 1994, Vol.35, 3357-3361. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G N Pomerance, D W Evans; Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy.. Invest. Ophthalmol. Vis. Sci. 1994;35(9):3357-3361.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: To determine the relationship between changes in contrast sensitivity, if any, after glaucoma therapy and the test-retest reliability of the CSV-1000 contrast sensitivity test. METHODS: Patients with primary open angle glaucoma (N = 16) were retrospectively evaluated to determine changes in visual function, as measured by contrast sensitivity, after beta-blocker therapy. A control group (N = 24) of normally sighted patients was tested and retested on contrast sensitivity. For the control group, the coefficients of repeatability (95% confidence interval for test-retest variability [COR]) were calculated for each spatial frequency. The CORs were compared to the changes in vision found after therapy in the patients with glaucoma. RESULTS: The group with glaucoma showed a significant improvement (P < .01) in contrast sensitivity at all spatial frequencies. The test-retest variance for normals, as measured by the COR, was smaller than the mean differences in contrast sensitivity before and after therapy at all spatial frequencies, expect 18 cyc/deg. CONCLUSIONS: Visual function in patients with glaucoma, as measured by contrast sensitivity, does improve after beta-blocker therapy. Further, the CSV-1000 is a clinically reliable tool for monitoring these changes.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×